News


 YS Biopharma Announces Name Change to LakeShore Biopharma

YS Biopharma Announces Name Change to LakeShore Biopharma

May 24, 2024 09:30 PM AEST| By Cision

GAITHERSBURG, Md., May 24, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discov...

 XCMG Machinery Amplifies Presence in Latin America with More Tailor-Made Machines Launched

XCMG Machinery Amplifies Presence in Latin America with More Tailor-Made Machines Launched

May 24, 2024 09:27 PM AEST| By Cision

SAO PAULO, May 24, 2024 /PRNewswire/ -- In a significant move to strengthen its foothold in the Latin American market, XCMG Machinery ("XCMG", SHE:000425) has ramped up its operations, marki...

 Rokid AR Lite: The first AR glasses powered by Snapdragon® 6 Gen 1 mobile platform

Rokid AR Lite: The first AR glasses powered by Snapdragon® 6 Gen 1 mobile platform

May 24, 2024 09:14 PM AEST| By Cision

REDWOOD CITY, Calif., May 24, 2024 /PRNewswire/ -- Rokid has announced the launch of its new AR device, the Rokid AR Lite, on Kickstarter, marking the first AR glasses powered by the Snapdra...

 Tapestry's Eric Chavous Selected for Minority Corporate Counsel Association’s 2024 Sources of Success™ Program

Tapestry's Eric Chavous Selected for Minority Corporate Counsel Association’s 2024 Sources of Success™ Program

May 24, 2024 09:04 PM AEST| By 3BL

Tapestry congratulates Eric Chavous, Senior Manager and Counsel at Tapestry on his acceptance into the Minority Corporate Counsel Association’s 2024 Sources of Success™ Program. A highly competitive p...

 Air Premia, Celebrates the First Anniversary of Its New York Route with Exceptional Performance

Air Premia, Celebrates the First Anniversary of Its New York Route with Exceptional Performance

May 24, 2024 09:00 PM AEST| By Cision

In its first year of service, Air Premia's Incheon-New York route has quickly established itself as a preferred choice for travelers. To celebrate this milestone, Air Premia is offering a limi...

 61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals

61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals

May 24, 2024 09:00 PM AEST| By Cision

STOCKHOLM, May 24, 2024 /PRNewswire/ -- A pioneering study, presented today at the 61st ERA Congress, has demonstrated that semaglutide significantly reduces the risk of major kidney disease events, c...

 A Positive State of Well-Being

A Positive State of Well-Being

May 24, 2024 09:00 PM AEST| By 3BL

Well-being offerings are not just a benefit for employees – they’re an expectation. In fact, in a recent study, 9 out of 10 employees said that well-being offerings impacted their decision-making...

 ARCHIPELAGO INTERNATIONAL CONTINUES EXPANSION IN THE CARIBBEAN AND LATIN AMERICA WITH PLANNED NEW OPENINGS, MULTIPLE SIGNINGS AND NEW CORPORATE OFFICES IN PUNTA CANA

ARCHIPELAGO INTERNATIONAL CONTINUES EXPANSION IN THE CARIBBEAN AND LATIN AMERICA WITH PLANNED NEW OPENINGS, MULTIPLE SIGNINGS AND NEW CORPORATE OFFICES IN PUNTA CANA

May 24, 2024 08:31 PM AEST| By Cision

PUNTA CANA, Dominican Republic, May 24, 2024 /PRNewswire/ -- Last week, at an official launch event in Punta Cana, attended by the Vice Minister for Tourism and the Indonesian Ambassador, Archi...

 Bybit Web3 Announces Upcoming IDO for Aperture Finance, Simplifying Web3 Finance

Bybit Web3 Announces Upcoming IDO for Aperture Finance, Simplifying Web3 Finance

May 24, 2024 08:28 PM AEST| By Cision

DUBAI, UAE, May 24, 2024 /PRNewswire/ -- Bybit Web3, the Web3 division of Bybit - one of the top three global crypto exchanges by trading volume, today announced an upcoming Initial DEX Offerin...

 K-Pet develops disease prevention solutions to extend the healthy life of pets

K-Pet develops disease prevention solutions to extend the healthy life of pets

May 24, 2024 08:13 PM AEST| By Cision

SEOUL, South Korea, May 24, 2024 /PRNewswire/ -- On the 23rd, K-PET ( http://k-pet.fourdpocket.com/) announced the development of a new pet disease prevention solution, tentatively named K-PET, utiliz...

 36Kr Hosts

36Kr Hosts "AI Partner • Advanced Productivity" Conference

May 24, 2024 08:00 PM AEST| By Cision

BEIJING, May 24, 2024 /PRNewswire/ -- 36Kr Holdings Inc. ("36Kr" or the "Company") (NASDAQ: KRKR), a prominent brand and a pioneering platform dedicated to serving New Economy part...

 Atour Unveils Sustainability Records in 2023 With Milestone ESG Report

Atour Unveils Sustainability Records in 2023 With Milestone ESG Report

May 24, 2024 08:00 PM AEST| By Cision

SHANGHAI, May 24, 2024 /PRNewswire/ -- May 23, Atour Lifestyle Holdings Limited (NASDAQ: ATAT), a leading hospitality and lifestyle company in China, has released its inaugural Environmental, Social,...

 CNFinance to Hold Annual General Meeting on June 7, 2024

CNFinance to Hold Annual General Meeting on June 7, 2024

May 24, 2024 08:00 PM AEST| By Cision

GUANGZHOU, China, May 24, 2024 /PRNewswire/ -- CNFinance Holdings Limited (NYSE: CNF) ("CNFinance" or the "Company"), a leading home equity loan service provider in China, tod...

 Lights On! Harbour City transforms for Vivid Sydney 2024

Lights On! Harbour City transforms for Vivid Sydney 2024

May 24, 2024 07:43 PM AEST| By Cision

Download high-res images & broadcast-quality vision of Vivid Sydney 2024 HERE Tickets available from vividsydney.com SYDNEY, May 24, 2024 /PRNewswire/ -- Vivid Sydney 2024 has kicked off its...

 Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting

May 24, 2024 07:36 PM AEST| By Cision

The ELECTRA and ELEVATE studies were designed to overcome different resistance mechanisms and improve patient outcomes with oral-oral combination options. Updated results from the ELECTRA stud...

 Friso Launches #MovetoGoodPoop Movement to Champion Good Gut Health in Children with Music and Storytelling

Friso Launches #MovetoGoodPoop Movement to Champion Good Gut Health in Children with Music and Storytelling

May 24, 2024 07:30 PM AEST| By Cision

Homegrown singer-songwriter-producer Derrick Hoh announced as Friso Brand Ambassador for 2024/25 SINGAPORE, May 24, 2024 /PRNewswire/ -- Friso, a leading nutrition formula milk brand with over 15...

 URBAN SPORTS AND STREET ARTS MEET IN SINGAPORE AS PART OF A GLOBAL WARM-UP TO THE PARIS 2024 OLYMPIC GAMES

URBAN SPORTS AND STREET ARTS MEET IN SINGAPORE AS PART OF A GLOBAL WARM-UP TO THE PARIS 2024 OLYMPIC GAMES

May 24, 2024 07:11 PM AEST| By Cision

The unique event, which is among the first global events created to build excitement for the upcoming Olympic Games, sees French and Singaporeans athletes and artists coming together to revitalis...

 New Oriental Extends Share Repurchase Program

New Oriental Extends Share Repurchase Program

May 24, 2024 07:00 PM AEST| By Cision

BEIJING, May 24, 2024 /PRNewswire/ -- New Oriental Education & Technology Group Inc. ("New Oriental" or the "Company") (NYSE: EDU and SEHK: 9901), a provider of private ed...

 Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a Selective and Orally Bioavailable KRAS G12D Inhibitor

Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a Selective and Orally Bioavailable KRAS G12D Inhibitor

May 24, 2024 06:33 PM AEST| By Cision

SHANGHAI, May 24, 2024 /PRNewswire/ -- Tyligand Bioscience, a clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies, announced that the firs...

 Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

May 24, 2024 06:32 PM AEST| By Cision

Anittumor efficacy of sunvozertinib was observed in patients regardless of baseline EGFR exon20ins status in plasma ctDNA. Sunvozertinib could effectively clear EGFR exon20ins in plasma ctDNA,...

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

Recent Articles